ArticleBioinformatics (Oxford, England)2026
RLAnOxPeptide: an integrated framework combining transformer and reinforcement learning for efficient antioxidant peptide prediction and innovative design.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
motivationBioactive peptides exhibit immense potential in pharmaceutical and food science domains, with antioxidant peptides (AOPs) garnering significant attention for their roles in scavenging free radicals. However, traditional discovery methods are inefficient and costly. This study introduces RLAnOxPeptide, an integrated computational framework that merges machine learning and reinforcement learning for the efficient prediction and de novo design of AOPs.
resultsThe framework initially establishes a high-precision predictor, RLP-T5Pred, based on the ProtT5 model via a 'protein-to-peptide' knowledge transfer strategy. By employing label smoothing and logit penalty regularization, it achieves state-of-the-art accuracy (AUC-ROC: 0.9692) and robust calibration. The second component is the generator, RLP-T5Gen, which is trained in an iterative 'Yin-Yang' loop combining supervised learning (to maintain sequence syntax) and reinforcement learning (to drive innovation). Guided by RLP-T5Pred serving as a fixed evaluator and a multi-objective reward function, the generator efficiently designs novel AOPs with high predicted activity. We experimentally validated the framework by synthesizing 17 designed peptides. Most candidates demonstrated potent radical scavenging abilities in chemical assays (DPPH and ABTS), leading to the selection of the top five candidates for cellular validation. In a t-BHP-induced HepG2 cell model, peptides Pep4, Pep5, Pep10, and Pep11 exhibited significant protective effects against oxidative damage. Consequently, the RLAnOxPeptide framework provides a powerful, experimentally verified paradigm for accelerating the discovery of novel antioxidant peptides. AVAILABILITY: The datasets generated and/or analysed during the current study, along with model outputs and representative peptide sequences, have been deposited in a public repository. The RLAnOxPeptide framework source code is available at GitHub: https://github.com/changshh/RLAnOxPeptide. An archival snapshot of the code used to perform the experiments described in this manuscript has been deposited in Zenodo with the DOI: 10.5281/zenodo.20078425. An interactive online demonstration is also available via Hugging Face Spaces: https://huggingface.co/spaces/chshan/RLAnOxPeptide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.